Full-Time

Senior Director

PMO

Novanta

Novanta

1,001-5,000 employees

Provides core photonics for medical tech

No salary listed

Berlin, Germany

In Person

Category
Business & Strategy (1)
Required Skills
Risk Management
Requirements
  • 8–12+ years of progressive experience in project, program, or portfolio leadership roles
  • Managing technical product development: Hardware/Software with regulated products is a must have
  • Proven track record leading Project Managers and delivering complex, cross-functional portfolios
  • Strong business acumen with experience balancing delivery performance, financial accountability, and strategic priorities
  • Ability to synthesize complex inputs, anticipate risks, and make decisive, outcome‑oriented decisions
  • Demonstrated leadership courage to enforce accountability and address underperformance
  • Deep understanding of project management methodologies and governance in matrixed organizations
Responsibilities
  • Has direct ownership of the performance, effectiveness, and accountability of Project and Program Managers
  • Establishes clear delivery expectations, execution standards, and accountability rules linked to PTQ, milestone reliability, and commitment adherence
  • Actively manages performance through clear consequences, including corrective actions, increased governance, reassignment, or escalation in cases of sustained underperformance
  • Ensures Project Managers operate with a full ownership mindset, proactively identifying risks, escalating constraints, and driving recovery actions
  • Builds Project Management capability primarily through expectation setting, performance management, and assignment to increasingly complex delivery challenges
  • Ensures succession readiness and capacity planning for Project Management roles in line with portfolio and business needs
  • Accountable for predictable portfolio delivery outcomes, including milestone reliability, schedule adherence, and PTQ/WAS performance
  • Owns PTQ and WAS KPIs, with a clear target of sustaining PTQ above 80%
  • Drives early identification and mitigation of delivery risks using leading indicators, not only lagging metrics
  • Resolves cross-functional priority conflicts and capacity constraints that threaten delivery commitments
  • Ensures consistent execution discipline across all projects in scope
  • Defines, implements, and enforces project management standard work, including governance cadence, escalation models, templates, and best practices
  • Ensures consistent governance across NPI and non-NPI projects as defined by MIS Leadership
  • Leads key project governance forums (e.g., weekly project reviews, leadership reviews), focusing on decisions, accountability, and outcomes
  • Ensures clear role clarity and decision rights between PMO, Product Management, R&D, Manufacturing, and Commercial functions
  • Ensures customer expectations and commitments are translated into realistic, executable project plans
  • Oversees preparation of clear, concise, outcome-oriented project status reporting for customers and senior management
  • Ensures timely and high-quality responses to customer and leadership inquiries
  • Escalates delivery risks decisively when commitments are at risk
  • Continuously improves PMO effectiveness through data-driven insights, lessons learned, and maturity assessments
  • Leverages NGS tools, systems, and processes to enhance transparency, predictability, and execution discipline
  • Drives a culture of ownership, accountability, and delivery excellence aligned with Novanta values
  • Recruits, hires, and develops PMO leadership and Project Management talent
  • Oversees the operational effectiveness and organizational health of the PMO
  • Conducts regular, outcome-oriented performance evaluations
  • Builds an engaged, resilient, and accountable PMO organization with a strong delivery mindset
  • Ensures strict compliance with quality, occupational safety, and environmental regulations
  • Responsible for maintaining safe and compliant working conditions within the PMO’s scope of responsibility
  • Implements and enforces all applicable quality, environmental, and occupational safety standards

Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bedford, Texas

Founded

1968

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 bookings surged 37% with 1.10 book-to-bill ratio signaling revenue acceleration.
  • Medical segment hit 53% of sales with double-digit consumables growth in 2026.
  • $1.5B acquisition capacity targets medical tech and bioprocessing for expansion.

What critics are saying

  • Allient erodes market share after beating Q4 estimates by 7.5% while Novanta misses.
  • 93x P/E ratio triggers 20-30% correction if Q2 growth disappoints in 3-6 months.
  • Tariffs and manufacturing transfers compress margins despite 100bps gain in 12 months.

What makes Novanta unique

  • Novanta supplies precision photonics, vision, and motion components to medical OEMs since 1968 origins.
  • Sole-source provider for AI data center GPU board precision drilling, capturing 15% revenue.
  • Showcased Denali drives and Aura encoders for surgical robotics at CMEF 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Novanta who can refer or advise you

Benefits

Health Insurance

Performance Bonus

Company News

Yahoo Finance
Mar 26th, 2026
Novanta falls 17% after revenue miss in otherwise strong Q4 for electronic components sector

As Q4 earnings season concludes, the nine electronic components stocks tracked showed strong performance, with revenues beating analyst consensus estimates by 3%. Share prices rose 5.2% on average since results were announced. Novanta posted revenues of $258.3 million, up 8.5% year-on-year, but fell short of analyst expectations by 0.9%. The company delivered the weakest performance against estimates in the group, with significant EBITDA misses. Its stock has dropped 17.4% since reporting, currently trading at $117.59. Allient led the group, reporting revenues of $143.4 million, up 17.5% year-on-year and beating expectations by 7.5%. The company also exceeded EBITDA estimates. Its shares have risen 6.3% since reporting, trading at $66.01.

EU-Startups
Mar 18th, 2026
Barcelona's Health Lean Analytics raises over $2.4M to automate hospital data with AI

Health Lean Analytics, a Barcelona-based startup automating hospital data collection, has raised over €2.1 million in a financing round combining private capital and public funding. US-listed Novanta joined as a technology and strategic partner, securing board representation. The round included an oversubscribed €1.4 million seed funding from family offices Inderhabs, Namarel and Braincats, plus a participative loan from Spain's National Innovation Company. Founded in 2023, HLA develops AI-powered hospital operations platforms that passively capture real-time clinical and operational data, particularly in surgical suites. The startup's technology integrates with existing hospital systems, using large language models to transform data into actionable insights. The funding will support domestic consolidation and US market entry within 12 months, whilst strengthening R&D capabilities in data automation and AI.

Yahoo Finance
Mar 4th, 2026
Harvey Partners bets $36M on Novanta despite flat stock performance

Harvey Partners disclosed a new position in Novanta, acquiring 304,000 shares worth $36.17 million during the quarter ending 17 February 2026, according to an SEC filing. The stake now represents 3.21% of the fund's reportable assets under management. Novanta, which provides photonics, vision and precision motion components for medical and industrial applications, has seen its shares remain roughly flat over the past year at around $145, significantly underperforming the S&P 500's 16% gain. The company reported revenue of $980.6 million in 2025, up 3% year over year, but operating income fell to $94 million from $110.6 million, whilst net income dropped from $64.1 million to $53.8 million. CEO Matthijs Glastra said the company plans to improve margins and cash flow this year.

Yahoo Finance
Feb 26th, 2026
Novanta CEO sells $1.1M worth of shares under pre-arranged trading plan

Novanta CEO Matthijs Glastra sold 7,500 common shares worth approximately $1.09 million on 10 February 2026, according to an SEC Form 4 filing. Following the transaction, Glastra holds 57,367 shares directly and 54,382 shares indirectly through a trust, with direct holdings valued at $8.3 million. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in September 2025, indicating routine liquidity management rather than concerns about company performance. The transaction matches Glastra's largest trade size in his 10 sell-only transactions since February 2023. Novanta manufactures photonics, vision and precision motion components for medical and industrial sectors, reporting $960.31 million in trailing twelve-month revenue and employing 3,000 people.

Yahoo Finance
Feb 24th, 2026
Novanta posts record Q4 on 25% bookings surge, targets $1.5B medical tech M&A

Novanta Inc. reported record fourth-quarter revenue and a return to organic growth, driven by a 25% surge in bookings across all business units. The precision technology company benefited from AI-driven demand in robotics, serving as the sole-source supplier for precision drilling of high-density GPU boards. Medical technology now represents 53% of total sales, with double-digit growth in consumables. However, the company experienced margin pressure due to regional manufacturing transfers, creating a temporary 100 basis point headwind. For 2026, Novanta projects mid-single-digit organic growth and 100 basis points of gross margin expansion once manufacturing transfers complete by Q2. The company plans to deploy nearly $1.5 billion in acquisition capacity towards medical technologies and bioprocessing. Operating cash flow is forecast at $145 million to $185 million.